Segment Description: Andrea L. Cox, MD, PhD, Professor of Medicine at Johns Hopkins University, discusses the increase in hepatitis C diagnoses since the start of the opioid epidemic.
Interview Transcript (modified slightly for readability):
Cox: Hepatitis C is a very important global pathogen. In addition, we're having significant difficulty in North America with rising rates of hepatitis C virus infections since the opioid epidemic began. Specifically, in 2010, when the opioid epidemic began, we were seeing about 10,000 new cases of hepatitis C annually. And since that time, we've now had a marked increase, and we're seeing closer to 50,000 new cases every year.
In contrast, hepatitis B, which is a vaccine preventable illness, the rates of that infection, which is also a blood borne pathogen, have been very stable.
I think this highlights the ability to prevent increases in infections for which we have effective vaccines, in the midst of an epidemic for which we don't have a vaccine.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512